🔗 Share this article

As the US continues making sweeping adjustments to its immunization schedules, a particular individual has surfaced in a surprising turn: Høeg, a US-based sports medicine doctor and public health researcher who initially gained attention by casting doubt on Covid shots in the pandemic and has zeroed in on alleged deaths following Covid vaccination in her brief position at the Food and Drug Administration.

Scheduled Shifts to Pediatric Immunization Schedule

Public health authorities were set to unveil sweeping revisions to the pediatric vaccine schedule recently, synchronizing the US with the Danish immunization schedule, according to reports – a significant shift that would place the US out of step with a large portion of the world with little proof for public health gain. The announcement has been pushed back until the new year.

Rather than the director of the vaccine center, Dr. Høeg is scheduled to present at the gathering. She was newly appointed interim head of the FDA’s drug evaluation center, the fifth individual to run the division this year.

A Shift at the Regulatory Body

Høeg's temporary position might represent a tighter collaboration between the drug and vaccine divisions as Høeg and Dr. Prasad solidify control at the FDA – and it signals a increased emphasis upon reevaluating previously authorized immunizations at the FDA.

Dr. Høeg has frequently advocated for halting some pediatric immunization guidelines in the US to become more similar to the Danish model, a society with comprehensive healthcare and a number of inhabitants about the population of the state of Wisconsin.

So far public appearances, she has persisted in emphasizing on immunizations – traditionally the responsibility of Prasad, head of the FDA’s vaccine center – as opposed to drug regulation.

Doubts Over Expertise

The appointee has little discernible track record in drug development, regulation or management, which has been typical for past leaders of the biologics center. She has worked at the FDA as a key advisor to the FDA chief and CBER since March.

“She doesn’t seem to have the necessary background” for leading the drug-regulation department, remarked a neurologist and psychiatrist. “She has not conducted a scientific study. She lacks experience in running a major agency. She is not an expert in pharmaceutical oversight.”

Past directors of CBER would “be deeply familiar with regulatory frameworks and the science of pharmaceutical innovation”, said a former acting FDA commissioner. “Objectively, she doesn’t have the type of experience that prior appointees who ran the center have had.”

The drug center has an immense workload at the FDA, Woodcock pointed out.

“Everybody just focuses on the novel medication approvals, but the generic drug division approves thousands of off-brand pharmaceuticals. There is also a biologic copycat branch, OTC medication office and other areas, and every single one have to be looked after,” she said. “The thing you don’t keep your eye on, that is precisely what that I always told people is going to bite you.”

There is also, a major leadership aspect to the job, which oversees more than 5,000 personnel. “It is a huge administrative position, if you perform it correctly,” she added.

Agency Reaction and Contentious Policies

Regarding inquiries about Høeg’s qualifications and whether this selection represents greater collaboration among regulatory chiefs on vaccines, a representative stated that the “inquiries stem from flawed assumptions”.

“Her resume matches the functions of her job,” the representative explained, citing the period Høeg spent advising the FDA commissioner on “medication safety and regulatory science, including predictive safety algorithms and vaccine surveillance”.

As acting director, Dr. Høeg assumes responsibility for the agency head's new expedited review system, a controversial rapid therapy clearance system that reportedly troubled her former heads. “How are these therapies being selected for this expedited pathway? Who makes the choices?” Howard questioned. “There’s a lot of confidentiality occurring at the agency right now.”

In general, he remarked, “the agency seems to be moving towards laxer regulations of pharmaceuticals, except for immunizations.”

Public Track Record on Immunizations

With immunizations, Dr. Høeg has a clearer, if troubling, track record, critics have noted. She released a analysis using unconfirmed crowd-sourced reports to determine the rate of myocarditis following Covid immunization. She counseled the state of Florida chief medical officer Joseph Ladapo, who was said to have modified findings to suggest COVID-19 vaccinations are pose a greater threat than they are.

Among her “wish list” for the current federal leadership encompassed altering regulations for novel immunizations and halting “non-essential” vaccines, she said post-election on a audio program. At the FDA, Dr. Høeg has reportedly suggested barring adolescent males from getting Covid vaccinations.

“She’s an thorough dogmatist who starts off with her preconceived notions and works backwards to accommodate the science in a very deceptive, fraudulent manner,” Howard argued.

Consolidating Power and a “Campaign of Retribution”

Dr. Høeg became part of fellow contrarians, {like|